Informations

Background of Research Selection and Recommendations Under the guidance of the Chinese Society of Clinical Oncology (CSCO), Peking University Library retrieved 6,435 publications on colorectal cancer from the SCI database.…

Recently, Dr. Yongsheng Li’s team from Chongqing University Cancer Hospital published a comprehensive review titled “Antibody-drug conjugates in cancer therapy: mechanisms and clinical studies” in the high-impact journal MedComm (IF:…

The MORPHEUS Phase Ib/II trial explores a transformative approach in clinical research by integrating real-world data (RWD) as a hybrid control arm to supplement traditional randomized controlled trials (RCTs) in pancreatic ductal adenocarcinoma (PDAC).

A recent publication in Diagnostics delves into the critical comparison between two cutting-edge molecular techniques—Methyl-BEAMing and Droplet Digital PCR (ddPCR)—for detecting MGMT gene promoter hypermethylation. This biomarker plays a pivotal role in various cancers, particularly glioblastomas, as it helps predict patient response to alkylating agent-based chemotherapy.

The phase II LUMEN study explores the dynamic changes in dosimetric parameters during Peptide Receptor Radionuclide Therapy (PRRT) with [177Lu]Lu-DOTA-TATE for patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The study reveals significant variability in absorbed doses and activity concentrations, particularly when comparing tumor sites to organs-at-risk such as the kidneys and red marrow. In pancreatic NETs,…

The incidence of gastroesophageal cancers is on the rise, driven by factors such as obesity and gastroesophageal reflux. Despite increased awareness and screening efforts, many cases are diagnosed at an advanced, unresectable stage, making effective systemic treatments critical for improving survival and quality of life.

A new international Delphi consensus led by valuable researchers provides crucial guidance on the design and endpoints of clinical trials for Acute Severe Ulcerative Colitis (ASUC). This comprehensive consensus, developed with input from global experts, establishes 30 key statements that define essential aspects of ASUC trial design.